摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-cyclopropyl-5-methoxy-4,6-pyrimidinediol | 617716-03-7

中文名称
——
中文别名
——
英文名称
2-cyclopropyl-5-methoxy-4,6-pyrimidinediol
英文别名
2-cyclopropyl-4-hydroxy-5-methoxy-1H-pyrimidin-6-one
2-cyclopropyl-5-methoxy-4,6-pyrimidinediol化学式
CAS
617716-03-7
化学式
C8H10N2O3
mdl
——
分子量
182.179
InChiKey
MNULXZMVIZYHNX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.59±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.2
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    70.9
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    2-cyclopropyl-5-methoxy-4,6-pyrimidinediolN,N-二乙基苯胺三氯氧磷 作用下, 生成 N,2-dicyclopropyl-5-methoxy-6-(4-thiomorpholinyl)-4-pyrimidinamine
    参考文献:
    名称:
    First dual M3 antagonists-PDE4 inhibitors: Synthesis and SAR of 4,6-diaminopyrimidine derivatives
    摘要:
    SAR around 4,6-diaminopyrimidine derivatives allowed the discovery of the first potent dual M-3 antagonists and PDE4 inhibitors. Various chemical modulations around that scaffold led to the discovery of ucb-101333-3 which is characterized by the most interesting profile on both targets. (C) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2006.01.006
  • 作为产物:
    参考文献:
    名称:
    [EN] POLO LIKE KINASE 4 INHIBITORS
    [FR] INHIBITEURS DE KINASE DE TYPE POLO 4
    摘要:
    本文披露了公式(I)的化合物或其药学上可接受的盐,它们是Polo Like Kinase 4(PLK4)的抑制剂。本文还披露了包含公式(I)的化合物或其药学上可接受的盐以及一个或多个药学上可接受的辅料的制药组合物。本文还披露了治疗需要的患者的癌症的方法,包括向患者投与公式(I)的化合物或其药学上可接受的盐的量。公式(I):
    公开号:
    WO2022240876A1
点击查看最新优质反应信息

文献信息

  • [EN] 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE 4,5,6-TRISUBSTITUÉE COMME INHIBITEURS DU FACTEUR IXA
    申请人:SCHERING CORP
    公开号:WO2011017296A1
    公开(公告)日:2011-02-10
    The present invention relates to novel heterocyclic compounds of Formulae (I): (Chemical formula should be inserted here as it appears on abstract in paper form) Formula (I) as disclosed herein, or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder.
    本发明涉及公式(I)的新颖杂环化合物:(化学式应按照纸质摘要中的形式插入此处)如本文所披露的公式(I),或其药学上可接受的盐、溶剂化合物、酯、前药或立体异构体。还披露了包括所述化合物的药物组合物,以及使用所述化合物治疗或预防血栓栓塞性疾病的方法。
  • [EN] CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS<br/>[FR] COMPOSES CHIMIQUES A DOUBLE ACTIVITE, PROCEDES DE LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES
    申请人:UCB SA
    公开号:WO2003087064A1
    公开(公告)日:2003-10-23
    The present invention concerns chemical compounds combining affinity and antagonism against the human m3 muscarinic receptor with activity as selective phosphodiesterase IV (PDE IV) inhibitors, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    这项发明涉及化学化合物,它们既具有对人类m3肌肉收缩素受体的亲和力和拮抗作用,又具有作为选择性磷酸二酯酶IV(PDE IV)抑制剂的活性,以及制备它们的方法、含有它们的药物组合物以及它们作为药物的用途。
  • Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions
    申请人:Provins Laurent
    公开号:US20060074068A1
    公开(公告)日:2006-04-06
    The present invention concerns chemical compounds combining affinity and antagonism against the human m3 muscarinic receptor with activity as selective phosphodiesterase IV (PDE IV) inhibitors, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    本发明涉及一种化学化合物,它们具有亲和力和拮抗作用,针对人类m3肌动蛋白受体,并具有选择性磷酸二酯酶IV(PDE IV)抑制剂的活性,制备它们的过程,包含它们的制药组合物以及它们作为药物的用途。
  • 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS
    申请人:Chelliah Mariappan V.
    公开号:US20120136016A1
    公开(公告)日:2012-05-31
    The present invention relates to novel heterocyclic compounds of Formulae (I): (Chemical formula should be inserted here as it appears on abstract in paper form) Formula (I) as disclosed herein, or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder.
    本发明涉及一种新的杂环化合物,其化学式为(I):(化学式应按纸质摘要中的形式插入此处)如本文所述的化合物(I)或其药学上可接受的盐、溶剂合物、酯、前药或立体异构体。本文还揭示了包括所述化合物的制药组合物,以及使用所述化合物治疗或预防血栓栓塞性疾病的方法。
  • CHEMICAL COMPOUNDS WITH DUAL ACTIVITY, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
    申请人:UCB, S.A.
    公开号:EP1499598A1
    公开(公告)日:2005-01-26
查看更多